Webcast ImageWebcast
Q1 2016 Clovis Oncology, Inc. Earnings Conference Call (Live)
05/05/16 at 4:30 p.m. ET
Q1 2016 Clovis Oncology, Inc. Earnings Conference Call
Thursday, May 5, 2016 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine – More >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.59 (4.06%)
Intraday High$14.57
Intraday Low$13.90
Data as of 05/03/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
04/26/16Clovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 26, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis On... 
Printer Friendly Version 
04/12/16Trading of Clovis Oncology, Inc. Common Stock Halted
FDA’s Oncologic Drugs Advisory Committee to Review Rociletinib New Drug Application for the Treatment of Non-Small Cell Lung Cancer BOULDER, Colo.--(BUSINESS WIRE)--Apr. 12, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this morning to discuss the company’s New Drug Application ... 
Printer Friendly Version 
04/12/16Clovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 12, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss approval of the New Drug Application (NDA) for rociletinib, an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-... 
Printer Friendly Version 
Upcoming EventsMore >>
4:30 p.m. ET
Q1 2016 Clovis Oncology, Inc. Earnings Conference Call
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.